SCHEMBL1820547

SCHEMBL1820547

O=C(O)c1ccc(I)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.63
CASP1 P29466 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
MAP2K1 Q02750 2/20 0.53
ALDH1A1 P00352 2/20 0.50
MYC P01106 1/20 0.49
NR4A1 P22736 1/20 0.49
TP53 P04637 1/20 0.47
PTPRC P08575 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPRA P18433 1/20 0.46
PTPRB P23467 1/20 0.46
PTPRE P23469 1/20 0.46
PTPN6 P29350 1/20 0.46
GRIK1 P39086 2/20 0.45
TPMT P51580 1/20 0.43
CYP1A2 P05177 1/20 0.42
SRD5A2 P31213 1/20 0.42
XDH P47989 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL305505 0.83 ALDH1A1 (0.63) TSHRCASP1SMN1; SMN2MAP2K1ALDH1A1
SCHEMBL1164647 0.83 TSHR (0.42) TSHRCASP1SMN1; SMN2MAP2K1ALDH1A1
SCHEMBL31364369 0.83 ALDH1A1 (0.63) TSHRCASP1SMN1; SMN2MAP2K1ALDH1A1
SCHEMBL7127279 0.81 MAP2K1 (0.41) TSHRCASP1SMN1; SMN2MAP2K1ALDH1A1
SCHEMBL27994220 0.81 ALDH1A1 (0.61) TSHRCASP1SMN1; SMN2MAP2K1ALDH1A1
SCHEMBL3376548 0.81 KMT2A (0.53) TSHRCASP1SMN1; SMN2MAP2K1ALDH1A1
SCHEMBL522679 0.79 PTPN1 (0.55) TSHRCASP1SMN1; SMN2MAP2K1ALDH1A1
SCHEMBL28060346 0.79 SRD5A2 (0.51) CASP1ALDH1A1NR4A1TP53CYP1A2
SCHEMBL2770320 0.77 TSHR (0.68) TSHRCASP1SMN1; SMN2ALDH1A1MYC
SCHEMBL111279 0.77 TSHR (1.00) TSHRCASP1SMN1; SMN2ALDH1A1MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438295-B1 AZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MERCK SERONO SA (CH) 2012-08-15 EP claimed
EP-1216045-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS American Cynamid Company (US) 2002-06-26 EP claimed
WO-2001022969-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS AMERICAN CYNAMID COMPANY (US) 2001-04-05 WO claimed
EP-4663632-A1 COMPOUNDS USEFUL FOR THE MODULATION OF THE ACTIVITY OF STING Sulis Therapeutics ApS (DK) 2025-12-17 EP disclosed
EP-3632910-B1 3,4-DIHYDROQUINOLINONES AS FXR RECEPTOR AGONISTS CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2024-07-17 EP disclosed
EP-3953360-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) HOFFMANN LA ROCHE (CH) 2024-02-28 EP disclosed
US-20230384676-A1 RADIATION-SENSITIVE RESIN COMPOSITION, METHOD OF FORMING PATTERN, POLYMER, AND COMPOUND JSR CORPORATION (JP) 2023-11-30 US disclosed
US-20230384676-A1 RADIATION-SENSITIVE RESIN COMPOSITION, METHOD OF FORMING PATTERN, POLYMER, AND COMPOUND JSR CORPORATION (JP) 2023-11-30 US disclosed
US-11774853-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-10-03 US disclosed
US-11774853-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-10-03 US disclosed
US-20230273519-A1 RADIATION-SENSITIVE RESIN COMPOSITION AND PATTERN FORMATION METHOD JSR CORPORATION (JP) 2023-08-31 US disclosed
WO-1996016046-A2 NOVEL BENZYL PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 1996-05-30 WO disclosed
EP-0679630-A1 Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1995-11-02 EP disclosed
EP-0674629-A1 4-BENZOYL ISOXAZOLES DERIVATIVES AND THEIR USE AS HERBICIDES RHONE-POULENC AGRICULTURE LTD. (GB) 1995-10-04 EP disclosed
EP-0661258-A1 Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1995-07-05 EP disclosed
WO-1995016678-A1 4-BENZOYLISOXAZOLES AND THEIR USE AS HERBICIDES RHONE POULENC AGRICULTURE LIMITED (GB) 1995-06-22 WO disclosed
EP-0658553-A1 Polycyclic aromatic compounds, pharmaceutical compositions containing them and uses thereof CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1995-06-21 EP disclosed
CN-1089258-A New herbicides RHONE POULENC AGRICULTURE (GB) 1994-07-13 CN disclosed
WO-1994014782-A1 4-BENZOYL ISOXAZOLES DERIVATIVES AND THEIR USE AS HERBICIDES RHONE-POULENC AGRICULTURE LTD. (GB) 1994-07-07 WO disclosed
EP-0409634-A2 Liquid crystal compounds and optically active compounds SANYO CHEMICAL INDUSTRIES LTD. (JP) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230384676-A1 RADIATION-SENSITIVE RESIN COMPOSITION, METHOD OF FORMING PATTERN, POLYMER, AND COMPOUND RER1, RFT1, RAD51 TSHR 2652/4885CASP1 2039/4885SMN1; SMN2 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.